Securities code: 301126 securities abbreviation: Dajia Weikang Announcement No.: 2022-004 Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd
Announcement on resolutions of the 9th meeting of the 3rd board of directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Convening of board meeting
The ninth meeting of the third board of directors of Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd. (hereinafter referred to as “the company”) was held in the company’s conference room on January 12, 2022 in the form of on-site communication. The notice of the meeting was sent to all directors by mail on January 7, 2022. There were 9 directors who should attend the meeting, and 9 directors actually attended the meeting. The meeting was convened and presided over by Mr. Wang Yiqing, chairman of the board of directors. The supervisors and senior managers of the company attended the meeting as nonvoting delegates. The convening, convening and voting procedures of this meeting comply with the company law of the people’s Republic of China and other laws, regulations, normative documents and the relevant provisions of the articles of association.
2、 Deliberations of the board meeting
After careful deliberation by the directors attending the meeting, the following resolutions are formed:
(I) deliberated and passed the proposal on using raised funds to replace self raised funds invested in raised investment projects in advance and paid issuance expenses
After deliberation, the board of directors agreed to use the raised funds to replace the self raised funds of 38.8233 million yuan invested in the raised investment projects in advance and 7.6981 million yuan (excluding value-added tax) paid for the issuance expenses, totaling 46.5214 million yuan.
For details, please refer to the company’s website (www.cn. Info. Com. CN.) on the same day Announcement on using raised funds to replace self raised funds invested in raised investment projects in advance and paid issuance expenses disclosed on the. The independent directors expressed their independent opinions on the matter, and the recommendation institution Sinolink Securities Co.Ltd(600109) issued its verification opinions.
Voting results: 9 in favor, 0 against and 0 abstention.
(II) deliberated and passed the proposal on using part of the over raised funds to permanently supplement the working capital
After deliberation, the board of directors agreed that the company would use the over raised capital of 17 million yuan to permanently supplement the working capital. For details, please refer to the company’s website (www.cn. Info. Com. CN.) on the same day Announcement on permanent replenishment of working capital with part of over raised funds disclosed on the.
The independent directors expressed their independent opinions on the matter, and the recommendation institution Sinolink Securities Co.Ltd(600109) issued its verification opinions.
This proposal needs to be submitted to the general meeting of shareholders for deliberation.
Voting results: 9 in favor, 0 against and 0 abstention.
(III) the proposal on convening the first extraordinary general meeting of shareholders in 2022 was deliberated and adopted
The board of directors agrees that the company will hold the first extraordinary general meeting of shareholders in 2022 on January 28, 2022. For details, please refer to the company’s website on the same day（ http://www.cn.info.com.cn. ）Notice on convening the first extraordinary general meeting of shareholders in 2022 disclosed on the.
Voting results: 9 in favor, 0 against and 0 abstention.
3、 Documents for future reference
1. Resolutions of the 9th meeting of the 3rd board of directors;
2. Independent opinions of independent directors on matters related to the ninth meeting of the third board of directors.
It is hereby announced.
Board of directors of Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd. January 12, 2022
